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Background:  Hyperuricemia  is  associated  with  a higher  risk  of  death  in  patients  with  coronary  artery
disease  (CAD).  In contrast,  overweight  or obesity  was  associated  with  survival  beneﬁts  in this  population.
However,  the  relation  of body  mass  index  (BMI)  and  serum  uric  acid (SUA)  to  mortality  has  not  been
clariﬁed  in this  population.
Methods: We  studied  a  cohort  of 1202  patients  with  angiographic  CAD  from  the  ET-CHD  registry  during
1997–2003  in  Taiwan.  To  evaluate  the  relation  of  BMI  and  SUA  on  mortality,  the subjects  were  categorized
into  4 groups  by BMI   25 kg/m2 (overweight  or  obesity)  or  BMI  <  25 kg/m2 (normal-  or under-weight),
and  SUA levels  higher  or lower  than  the  median  of 6.6  mg/dl.  At a median  follow-up  of  5.4 years,  cardiac
and  all-cause  deaths  were  the  primary  end points.
Results: Multivariate  analyses  demonstrated  that  high  SUA  group  had  a signiﬁcantly  higher  cardiac  mor-
tality [hazard  ratio  (HR):  1.79,  95%  conﬁdence  interval  (CI):  1.14–2.82,  p = 0.023]  and overall  mortality
(HR: 1.68,  95%  CI: 1.19–2.36,  p =  0.003)  than  low  SUA  group  only  in  overweight  or obese  patients.  Addi-
tionally,  high  BMI  was  associated  with  a signiﬁcantly  lower  cardiac  mortality  (HR:  0.58,  95%  CI:  0.38–0.99,
p =  0.023)  and  overall  mortality  (HR:  0.62, 95%  CI: 0.41–0.82,  p = 0.003)  than  low  BMI  in  patients  with  low
2SUA  levels.  Furthermore,  normal-low  weight  and  underweight  patients  (BMI  <  21  kg/m )  were  found  to
have  a higher  risk  of  mortality  regardless  of SUA  levels.
Conclusions:  Among  patients  with  established  CAD,  SUA  may  be a potent  predictor  to  mortality  in  over-
weight  or obese  patients.  Moreover,  the  obesity-mortality  paradox  phenomenon  was  mainly  driven  by
higher  mortality  risk  in  underweight  patients  and  lower  mortality  risk  in  overweight  and  obese  patients
with  low  SUA.
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Serum uric acid (SUA) has been observed to be highly associ-
ted with the development of obesity and cardiovascular disease
or more than 50 years. Experimentally, uric acid could generate
minocarbonyl radicals which have proinﬂammatory and anti-
xidant effects on vascular smooth muscle cells subsequently
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leading to cardiovascular diseases [1,2]. In addition, uric acid has
also been found to have a role in the pathogenesis of vascular hyper-
tension and atherosclerosis [3,4]. Since uric acid is largely produced
by the vascular endothelium, elevated SUA may  be a marker of
endothelial dysfunction and clustered with the condition of obe-
sity, metabolic syndrome, and insulin resistance [5]. A number of
reports conﬁrmed that elevated SUA could be seen as an indepen-
dent predictor of mortality in patients with coronary artery disease
(CAD) after adjustment for classic risk factors [6–11]. In contrast,
overweight or obesity was found to be associated with a survival
beneﬁt in patients with established CAD. This has been known
as the obesity-mortality paradox phenomenon [12–14]. However,
there were no reports discussing the relation of body mass index
(BMI) and SUA to the mortality in CAD patients. Accordingly, we
vier Ltd. All rights reserved.
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ssessed the prognostic value of SUA levels for cardiac and over-
ll mortality in the overweight or obese patients (BMI  25 kg/m2)
nd the thinner ones (BMI < 25 kg/m2) with CAD in eastern Taiwan.
esides, the relation of BMI  on mortality was also evaluated at dif-
erent SUA levels. A retrospective cohort study was performed in
202 angiographically deﬁned CAD patients, and their classic risk
actors, BMI, and SUA levels were determined at entry. The study
ohort was followed for an average of 5.4 years, with a maximal 10
ears. The main outcome measure was death from cardiac disease
nd any cause.
ethods
tudy subjects
Between January, 1997 and December, 2003, a cohort of 1347
onsecutive patients was prospectively enrolled in the registry of
the Eastern Taiwan integrated health care delivery system of Coro-
ary Heart Disease (ET-CHD)” at Tzu-Chi General Hospital, Hualien,
aiwan. At enrollment, all study subjects were diagnosed to have
bstructive CAD based on angiographic evidence of at least one
ajor coronary artery or primary branch with a diameter stenosis
f ≥50%. We  excluded 73 patients with missing SUA data, and 72
ubjects with missing BMI  data at baseline. Thus, the ﬁnal sample
ize for this study was 1202.
aseline assessments
BMI  was deﬁned as weight (kg)/the square of height (m2) and
btained at entry. Blood samples were drawn from study patients
t the time of coronary angiography. The clinical chemistry was
easured by AU640e Chemistry Immuno Analyzer (AU640, Olym-
us, Tokyo, Japan). Clinical chemistry measurements used reagents
or the AU640: SUA, OSR6136, uricase method; total choles-
erol, OSR6116, enzymatic; aminoantipyrene/phenol/peroxidase
ethod; high-density lipoprotein (HDL) cholesterol, OSR 6287,
irect-no pretreatment enzymatic immuno-inhibition method;
riglyceride, OSR6133, glycerol phosphate oxidase method; creat-
nine, OSR6178, modiﬁed Jaffe kinetic method, and urea nitrogen,
SR6234, urease/GLDH method. Diabetes mellitus was  diagnosed
n patients with antidiabetic/insulin therapy or fasting blood
lucose >125 mg/dl at baseline. Hypertension was  diagnosed in
hose with antihypertensive therapy or baseline blood pressure
140/90 mmHg. The treatment procedure and medication were
erived from hospital discharge records.
ndpoint
The survival status and cause of death were ascertained by
inkage to the mortality database until December 31, 2006. The
ortality database, submitted standardized certiﬁcates for each
eath, mandatory for physicians by the Department of Health. So
he vital statistics published by the National Health Department
f Taiwan are complete, with a physician conﬁrmation rate of 99%.
his study was approved by the local ethics committee (IRB096-39).
tatistical analysis
The median SUA level for the entire cohort was 6.6 mg/dl, and
he medians for male and female patients were 6.7 and 6.6 mg/dl,
espectively. The median SUA level, 6.6 mg/dl, and the median BMI
alue, 25 kg/m2, were used to classify the study subjects into 4 study
roups: BMI  ≥ 25 kg/m2, SUA < 6.6 mg/dl (n = 282); BMI  ≥ 25 kg/m2,
UA ≥ 6.6 mg/dl (n = 340); BMI  < 25 kg/m2, SUA < 6.6 mg/dl
n = 298); BMI  < 25 kg/m2, SUA ≥ 6.6 mg/dl (n = 282). Baseline
haracteristics of patients were presented as percentages or aslogy 62 (2013) 354–360 355
mean ± SD. Chi-square tests were used to test baseline differences
across the study groups for categorical variables. Since most
continuous variables in this study did not follow a normal distri-
bution, Kruskal–Wallis test, a nonparametric method without the
requirement of normal assumption, was used to determine the
difference among the study groups.
The follow-up time for each subject, deﬁned as person-years at
risk, began with the examination date of angiography, and ended
with death or the end of the study period (December 31, 2006).
Kaplan–Meier survival curves were plotted to depict the overall
and cardiac death for the study subjects over time by the 4 study
groups. Curves were compared using the log-rank test. Cox pro-
portional hazard regression models were used to determine the
unadjusted and adjusted hazard ratios (HRs) for cardiac and overall
mortality associated with BMI  and SUA levels. To examine the inter-
action effect of BMI  and SUA on overall and cardiac mortality, BMI
by SUA interaction terms were incorporated into the Cox regression
models to compare the equality of BMI-group-speciﬁc or SUA-
group-speciﬁc HRs in all CAD patients. All potential confounders
listed in Table 1 were entered into the model; blood pressures,
total cholesterol/triglycerides, glucose, blood urea nitrogen levels,
and diuretic use were further removed from the ﬁnal model due
to their high association with the other covariates such as hyper-
tension, diabetes, congestive heart failure, high density lipoprotein
cholesterol, and creatinine levels. The validity of the proportional-
hazards assumption was tested by including the study groups and
time-varying covariates for each group in the regression model.
The assumption was  satisﬁed if the hazard ratio did not change
over time. No signiﬁcant deviation from the proportional-hazards
assumption was detected. All statistical analyses were performed
with SAS version 9.2 (SAS Institute, Cary, NC, USA). A p < 0.05 was
considered statistically signiﬁcant.
Results
Table 1 shows the baseline characteristics of CAD patients by
deﬁned BMI  and SUA groups. In general, patients with overweight
or obesity (BMI ≥ 25 kg/m2) were younger (64 years vs. 67 years)
and had higher proportions of hypertension (76% vs. 67%), diabetes
(39% vs. 33%), and dyslipidemia than their thinner counterparts. In
contrast, patients with normal- or under-weight (BMI < 25 kg/m2)
had more prevalence of pre-existing cancer and stroke and were
predisposed to having myocardial infarction at entry. Regarding
SUA effect, the higher SUA group (≥6.6 mg/dl) was  associated
with increased serum total cholesterol, triglycerides, heart failure,
impaired renal function and diuretic use as compared to the lower
SUA group (<6.6 mg/dl). With regard to medications, beta-blockers
and statins were more prescribed in patients with overweight
or obesity. There were only 17 (1.4%) patients taking allopurinol
and 13 (1.1%) patients taking benzbromarone for hyperuricemia.
Besides, aspirin was used by all study patients and diuretics were
mainly used for those with congestive heart failure or with a
reduced left ventricular ejection fraction. Two  hundred and sixty-
six of 309 patients with heart failure (86.1%) received diuretics at
baseline.
Therefore the presence of heart failure was highly correlated
with diuretic use.
As of December 2006, the mean (median) follow-up time was
5.4 (5.4) years for the 1202 study subjects. There were 394 deaths
including 226 (57.4%) cardiac deaths and 168 noncardiac deaths.
The 168 noncardiac deaths were due to neoplasms (n = 50), cere-
brovascular disease (n = 24), respiratory system disease (n = 21),
digestive system disease (n = 22), renal and urinary system disease
(n = 12), infectious disease (n = 8), injury and poison (n = 14), and
other or unknown causes (n = 17). Detailed information concerning
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Table 1
Baseline characteristics in coronary artery disease patients by study group.
Variables BMI  ≥ 25 BMI  ≤ 25 p
SUA < 6.6 (n = 282) SUA ≥ 6.6 (n = 340) SUA < 6.6 (n = 298) SUA ≥ 6.6 (n = 282)
BMI  (kg/m2) 28.2 ± 2.4 28.3 ± 2.7 22.6 ± 1.9 22.6 ± 2.0
Serum uric acid (mg/dl) 5.2 ± 1.0 8.6 ± 1.6 5.1 ± 1.1 8.4 ± 1.6
Age  (years) 64.0 ± 10.3 64.5 ± 10.9 66.5 ± 10.5 67.6 ± 10.7 <0.001
Male  (%) 77.0 73.2 70.1 75.9 0.240
Systolic blood pressure (mmHg) 132.5 ± 18.3 134.8 ± 20.8 130.8 ± 20.8 130.3 ± 18.7 0.029
Diastolic blood pressure (mmHg) 78.9 ± 10.9 78.4 ± 12.9 75.9 ± 12.2 75.8 ± 12.4 <0.001
Smoking status (%) 0.784
Nonsmoker 50.3 50.0 49.3 44.3
Ex-smoker 16.0 15.6 15.4 18.8
Current smoker 33.7 34.4 35.2 36.9
Medical history
Hypertension (%) 75.5 76.5 65.1 69.5 0.005
Congestive heart failure (%) 18.4 31.5 22.8 33.0 <0.001
Diabetes (%) 39.4 38.5 32.6 33.0 0.173
Cancer (%) 2.5 2.1 5.4 2.5 0.069
Stroke (%) 7.8 7.1 9.7 11.4 0.243
Laboratory ﬁndings
Total cholesterol (mg/dl) 183.8 ± 41.4 203.3 ± 50.9 183.1 ± 41.8 189.5 ± 48.5 <0.001
HDL  cholesterol (mg/dl) 41.5 ± 11.2 41.3 ± 11.1 44.5 ± 11.9 42.3 ± 11.2 0.004
Triglycerides (mg/dl) 164.9 ± 98.0 217.5 ± 147.3 142.7 ± 94.4 164.3 ± 114.44 <0.001
Fasting glucose (mg/dl) 145.6 ± 68.9 150.0 ± 74.4 140.9 ± 78.1 142.2 ± 74.5 0.634
Creatinine (mg/dl) 1.1 ± 0.3 1.5 ± 0.9 1.3 ± 1.2 1.5 ± 0.9 0.030
Blood  urea nitrogen (mg/dl) 18.3 ± 6.3 23.4 ± 11.7 20.0 ± 9.1 24.0 ± 11.3 <0.001
Clinical presentation
Diseased vessels (%) 0.020
Single-vessel 44.3 31.5 40.9 33.3
Double-vessel 19.2 24.7 19.1 23.1
Triple-vessel 36.5 43.8 39.9 43.6
Angina pectoris (%) 72.0 76.8 67.8 70.2 0.076
Myocardial infarction (%) 35.5 38.2 46.3 47.2 0.007
PCI  (%) 55.3 52.7 55.0 52.5 0.844
CABG  (%) 25.2 27.9 21.1 27.7 0.191
Medical therapy only (%) 23.1 23.5 27.9 24.5 0.520
Medication at enrollment
Diuretic (%) 15.3 27.4 16.8 28.4 <0.001
Calcium channel blockers (%) 45.4 37.4 42.6 37.6 0.125
ACE  inhibitor (%) 46.8 53.2 47.3 47.2 0.297
Beta-blocker (%) 40.8 43.2 38.3 30.9 0.013
Statin  (%) 16.3 20.0 14.8 12.4 0.069
Allopurinol (%) 1.1 2.1 1.3 1.1 0.744
Benzbromarone (%) 0.7 1.8 1.0 0.7 0.619
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cardiac mortality rates for high BMI/high SUA, low BMI/low SUA,
and low BMI/high SUA patients were 2.03, 3.91, 3.65, and 4.61 per
100 person-years, respectively. The cardiac mortality ﬁndings in
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istribution and causes of death for each study group is provided
n the supplementary material (Table S1).
Supplementary material related to this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.jjcc.2013.06.002.
Figs. 1 and 2 show the Kaplan–Meier survival curves for total
nd cardiac mortality for the 4 study groups, respectively. Over-
ll and cardiac mortality were signiﬁcantly lower in patients with
MI  ≥ 25 kg/m2 and SUA < 6.6 mg/dl than the other 3 study groups
p < 0.001).
Table 2 presents overall and cardiac mortality rates per 100
erson-years for the 4 study groups, respectively. The overall mor-
ality rates for high BMI/low SUA, high BMI/high SUA, low BMI/low
UA, and low BMI/high SUA patients were 3.63, 6.19, 7.24, and
.24 per 100 person-years, respectively. Multivariate Cox regres-
ion models, adjusted for co-morbidities and possible confounders,
howed that BMI-group-speciﬁc HRs associated with high SUA for
otal mortality for BMI  ≥ 25 kg/m2 and BMI  < 25 kg/m2 groups were
.68 (95% CI: 1.19–2.36) and 0.86 (95% CI: 0.64–1.14), respectively.
he signiﬁcant interaction effect between BMI  and SUA on over-
ll mortality (p = 0.003) indicated that elevated SUA was  a risk
actor for overall mortality in overweight or obese patients, but
as not a predictor among normal- or under-weight patients. Theous coronary intervention; CABG, coronary artery bypass grafting; ACE, angiotensin-Yea rs
Fig. 1. Kaplan–Meier survival curves for overall mortality in coronary artery disease
patients according to study groups. p < 0.001 by log-rank test. BMI, body mass index;
UA,  serum uric acid.
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Table 3
BMI  hazard ratios for total and cardiac mortality in coronary artery disease patients
by  uric acid group.
Study Group Crude HR (95% CI) Adjusted HRa (95% CI) pb
All-cause mortality
SUA < 6.6 mg/dl
BMI  ≥ 25 vs. BMI  < 25 0.51 (0.37–0.69) 0.58 (0.41–0.82) 0.003
SUA  ≥ 6.6 mg/dl
BMI  ≥ 25 vs. BMI  < 25 0.80 (0.62–1.05) 1.12 (0.85–1.49)
Cardiac mortality
SUA < 6.6 mg/dl
BMI  ≥25 vs. BMI  < 25 0.56 (0.37–0.86) 0.62 (0.38–0.99) 0.023
SUA  ≥ 6.6 mg/dl
BMI  ≥25 vs. BMI  < 25 0.85 (0.61–1.19) 1.22 (0.85–1.75)
BMI, body mass index; SUA, serum uric acid; HR, hazard ratio.
a Adjusted for age, smoking status, high-density lipoprotein cholesterol, creat-
inine, congestive heart failure, hypertension, diabetes, stroke, cancer, number of
blocked coronary arteries, angina pectoris, myocardial infarction, percutaneous
coronary intervention, coronary artery bypass grafting, and medication status
T
S
B
c
big. 2. Kaplan–Meier probabilities without cardiac death in coronary artery disease
atients according to study groups. p < 0.001 by log-rank test. BMI, body mass index;
A,  serum uric acid.
ox regression analysis were similar to those for overall mortality.
he signiﬁcant interaction effect between BMI  and SUA on cardiac
ortality (p = 0.023) also indicated that elevated SUA was a risk
actor for cardiac mortality (HR = 1.79, 95% CI: 1.14–2.82) in over-
eight or obese patients, but was not a predictor (HR = 0.91, 95%
I: 0.62–1.32) in normal- or under-weight patients. We  also ana-
yzed SUA level as a continuous variable, and the results were in
ine with the above ﬁndings. Elevated SUA was  associated with
igher overall and cardiac death in overweight or obese patients,
ut not among normal- or underweight weight patients (Table 2).
able 3 presents SUA-group-speciﬁc hazard ratios associated with
MI  for overall and cardiac mortality in multivariate Cox regres-
ion models. Among patients with low SUA (<6.6 mg/dl), high BMI
as associated with lower risk of death than low BMI  (HR = 0.58,
5% CI: 0.41–0.82). However, among patients with high SUA levels
≥6.6 mg/dl), the BMI  effect was not signiﬁcant. Similarly, for car-
iac mortality, in patients with low SUA, high BMI was associated
ith lower risk of cardiac death than low BMI  (HR = 0.62, 95% CI:
.38–0.99). Among patients with high SUA levels, the BMI  effect on
ardiac mortality was not signiﬁcant.
able 2
UA hazard ratios for total and cardiac mortality in coronary artery disease patients by BM
Study group Event (n) Annual mortality (%) 
Models using SUA group as a dichotomous covariate
All-cause mortality
BMI  ≥ 25, SUA ≥ 6.6 (n = 340) 111 6.19 
BMI  ≥ 25, SUA < 6.6 (n = 282) 59 3.63 
BMI  < 25, SUA ≥ 6.6 (n = 282) 111 7.75 
BMI  < 25, SUA < 6.6 (n = 298) 113 7.24 
Cardiac mortality
BMI  ≥ 25, SUA ≥ 6.6 (n = 340) 70 3.91 
BMI  ≥ 25, SUA < 6.6 (n = 282) 33 2.03 
BMI  < 25, SUA ≥ 6.6 (n = 282) 66 4.61 
BMI  < 25, SUA < 6.6 (n = 298) 57 3.65 
Models using SUA level (mg/dl) as a continuous covariate
All-cause mortality
BMI  ≥ 25 (n = 622) 
BMI  < 25 (n = 580) 
Cardiac mortality
BMI  ≥ 25 (n = 622) 
BMI  < 25 (n = 580) 
MI, body mass index; SUA, serum uric acid; HR, hazard ratio.
a Adjusted for age, smoking status, high-density lipoprotein cholesterol, creatinine, h
oronary arteries, angina pectoris, myocardial infarction, percutaneous coronary interv
lockers, angiotensin-converting enzyme inhibitors, statins, allopurinol/benzbromarone)
b p for the interaction effect between BMI  and SUA.(calcium channel blockers, angiotensin-converting enzyme inhibitors, statins, allop-
urinol/benzbromarone).
b p for the interaction effect between BMI and SUA.
Table 4 presents the multivariate Cox regression model for pre-
dicting all-cause mortality. In addition to the study group, variables
such as age, female gender, smoker, elevated creatinine level, dia-
betes, cancer, stroke, triple coronary artery disease, myocardial
infarction, congestive heart failure, and use of calcium channel
blockers were associated with an increased HR. Nevertheless, HDL
cholesterol level, percutaneous coronary intervention, coronary
artery bypass grafting, and use of a beta-blocker were associ-
ated with a decreased HR in the multivariate analysis. We  further
excluded the 30 patients with allopurinol or benzbromarone treat-
ment in the analysis, the results were not different from the ﬁndings
listed in Table 4.
To explore the BMI  effect on risk of death among patients
with high SUA levels (≥6.6 mg/dl), Fig. 3 presents the overall
mortality rates by 4 reﬁned BMI  categories. Patients with normal-
low or underweight (BMI < 21 kg/m2) had higher mortality (16.3
per 100 person-years) than the other BMI  groups. Fig. 4 depicts
I  group.
Crude HR (95% CI) Adjusted HRa (95% CI) pb
1.70 (1.24–2.34) 1.68 (1.19–2.36)
1 (reference) 1 (reference) 0.003
1.07 (0.82–1.39) 0.86 (0.64–1.14)
1 (reference) 1 (reference)
1.92 (1.27–2.90) 1.79 (1.14–2.82)
1 (reference) 1 (reference) 0.023
1.26 (0.88–1.80) 0.91 (0.62–1.32)
1 (reference) 1 (reference)
1.15 (1.08–1.23) 1.10 (1.03–1.17) 0.002
1.03 (0.97–1.09) 0.95 (0.89–1.01)
1.17 (1.08–1.27) 1.11 (1.02–1.20) 0.057
1.08 (1.00–1.17) 0.99 (0.91–1.07)
ypertension, congestive heart failure, diabetes, stroke, cancer, number of blocked
ention, coronary artery bypass grafting, and medication status (calcium channel
.
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Table 4
The hazard ratio of covariates in multivariate Cox regression analysis of all-cause
mortality.
Covariate Hazard ratio 95% CI p-value
Study group
BMI < 25, SUA ≥ 6.6 1.49 1.05–2.11 0.025
BMI  < 25, SUA < 6.6 1.74 1.22–2.47 0.002
BMI  ≥ 25, SUA ≥ 6.6 1.68 1.19–2.36 0.003
BMI  ≥ 25, SUA < 6.6 1 (reference)
Age (years) 1.06 1.05–1.07 <0.001
Female gender 1.52 1.16–1.99 0.002
Smoking status
Current smoker 1.36 1.00–1.84 0.046
Ex-smoker 1.30 0.99–1.70 0.051
Non-smoker 1 (reference)
HDL cholesterol (mg/dl) 0.99 0.98–1.00 0.005
Creatinine (mg/dl) 1.15 1.05–1.26 0.002
Congestive heart failure 2.78 2.22–3.49 <0.001
Diabetes 1.67 1.34–2.10 <0.001
Hypertension 0.99 0.79–1.28 0.945
Cancer 2.00 1.29–3.14 0.002
Stroke 1.52 1.10–2.06 0.010
Number of blocked vessels
Triple-vessel 1.51 1.13–2.00 0.005
Double-vessel 1.15 0.86–1.57 0.349
Single-vessel 1 (reference)
Angina pectoris 0.98 0.77–1.24 0.869
Myocardial infarction 1.48 1.17–1.88 0.001
Treatment group
PCI 0.80 0.63–1.01 0.061
CABG 0.70 0.52–0.93 0.015
Medication only 1 (reference)
Calcium channel blockers 1.27 1.01–1.58 0.038
ACE inhibitor 0.91 0.73–1.14 0.424
Beta-blocker 0.79 0.63–0.99 0.041
Statin 1.05 0.75–1.46 0.776
Allopurinol/benzbromarone 0.76 0.39–1.47 0.412
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In this report, we elucidated the effects of BMI  and SUA onMI, body mass index; SUA, serum uric acid; HDL, high-density lipoprotein; PCI,
ercutaneous coronary intervention; CABG, coronary artery bypass grafting; ACE,
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verall mortality rates among patients with low BMI by 4 reﬁned
UA categories. There were no mortality differences across the four
UA groups in patients with BMI  < 25 kg/m2.
Fig. 5 presents the scatter plot of the baseline SUA and BMI  levels.
here was weak correlation (r = 0.11, p < 0.001) between the SUA
nd BMI  levels; however, this weak association did not affect the
nteraction ﬁndings of the two variables on the mortality outcomes.iscussion
The ET-CHD registry was conducted in the Buddhist Tzu-
hi General Hospital which was the only cardiovascular referral
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ig. 3. Overall mortality rate per 100 person-years by body mass index (BMI) cate-
ory in 622 coronary artery disease patients with serum uric acid level ≥ 6.6 mg/dl.Fig. 4. Overall mortality rate per 100 person-years by serum uric acid category in
580  coronary artery disease patients with body mass index < 25 kg/m2.
center in Hualien and Taitung, two of the largest counties in Taiwan
to carry out angiography for patients with symptomatic CAD from
1997 to 2003 [11]. Therefore, the selection bias for low-risk patients
with obstructive CAD could be largely eliminated, and instead
this reﬂected that there were higher proportions of comorbidi-
ties, severe CAD, and treatment with coronary interventions in the
ET-CHD cohort which was  similar to other CAD cohorts by angiog-
raphy worldwide [13,14]. Of note, the annual total mortality rate
of 6.1% in our cohort was obviously higher than those in many
recent CAD cohorts. For instance, in REACH registry, 2005–2008
the mortality rate was  4.0% and the SYNTAX trial, 2006–2010,
2.2% [15,16]. The mortality discrepancies could be explained as
follows. First, in our registry there were around 70% patients
with acute coronary syndrome and over 40% patients with acute
myocardial infarction. Second, all patients were enrolled before
2004 when drug-eluting stents and potent antiplatelet agents such
as clopidogrel were rarely used in Taiwan. In the meantime, the
evidence-based practice to treat ischemic heart disease was  rela-
tively lacking at that time (wherein beta-blocker use rate was less
than 40% and statin use rate was  less than 20%). Third, the catch-
ment area of Tzu-Chi General Hospital covers two geographically
largest counties in Taiwan, spanning over 300 kilometers in length.
Patients with acute coronary syndrome were probably deferred
to receive primary coronary interventions, resulting in irreversible
myocardial necrosis and subsequent heart failure.mortality among patients with established CAD. Two  signiﬁcant
ﬁndings should be emphasized. First, elevated SUA  was  an inde-
pendent predictor of a higher cardiac or overall mortality merely in
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Fig. 5. Scatter plot of body mass index and serum uric acid.
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verweight and obese patients, but not in normal and underweight
ounterparts. Second, high BMI  (overweight and obesity) was asso-
iated with a lower cardiac and overall mortality than low BMI
normal and underweight) in patients with low SUA levels. Third,
atients with normal-low BMI  and underweight (BMI < 21 kg/m2)
ad a higher risk of mortality regardless of SUA levels.
Over the past two decades, there were many debates on the
ausal role of SUA in the development of cardiovascular disease or
ll-cause death. To the best of our knowledge, elevated SUA is pro-
ortional to an increased rate of waste production and a decreased
ate of renal excretion. Clinically, elevated SUA was also related
o purine-rich diet intake, alcohol, obesity, metabolic disorders,
mpaired renal function, and diuretic treatment. Nearly all these
onditions were common in our patients with higher SUA. In the
eneral population, the Framingham Heart Study showed the asso-
iation between SUA and mortality could be attributed to other risk
actors such as hypertension, dyslipidemia, and diabetes [17]. In
ontrast, the Finland study revealed that SUA was  a strong predic-
or of death from cardiovascular disease and any causes in healthy
iddle-aged men, independent of variables commonly associated
ith gout or the metabolic syndrome [18]. Speciﬁcally, among
atients with angiographically proven CAD, the majority of reports
greed consistently that SUA was an independent predictor of car-
iac and overall death [11,19–22].
Obesity is usually clustered with many metabolic abnormal-
ties and related to a higher risk for cardiovascular disease and
eath in the general population. However, the epidemiologic stud-
es have found the obesity-mortality paradox phenomenon among
atients with established coronary heart disease or CAD equiva-
ents such as heart failure, end-stage renal disease, and diabetes
23,24]. Therefore, a clinical concern is generated about the risk
f mortality when the BMI  meets SUA among CAD patients. In
ur report, SUA levels were not associated with a mortality risk in
ormal- or under-weight patients with obstructive CAD. Since SUA
s the metabolite of purine, which is mainly taken from meat, the
ower SUA levels may  reﬂect a poor nutritional status in clinically
ll patients with lower BMI  [25]. The dual hazardous effects of high
nd low SUA on the mortality may  be offset to produce a neutralized
esult among the thinner CAD population. Apparently in our report,
mong patients with low BMI, there was a higher cardiac death rate
n high SUA group but a higher non-cardiac death rate in low SUA
roup (Table S1). In this respect, malnutrition-inﬂammation com-
lex syndrome and endotoxin-lipoprotein hypothesis have been
roposed to be the mechanisms underlying the higher risk of mor-
ality [26,27].
In contrast, elevated SUA was an independent factor for death
n overweight or obese patients. Actually, many reports have con-
rmed that metabolically healthy obese people were found with a
ower inﬂammatory and insulin-resistant status and at reduced risk
f cardiovascular disease and all-cause mortality compared with
he metabolically unhealthy obese and the thinner ones in gen-
ral population [28–30]. Our report further extends the knowledge
o the patients with established CAD. Among patients with over-
eight and obesity, lower SUA was associated with less metabolic
bnormalities and hence was at reduced risk of mortality. On the
ontrary, the overweight and obese patients with higher SUA were
bserved with an increased risk for metabolic syndrome and car-
iac or all-cause mortality. This ﬁnding was compatible to previous
eports that the metabolic syndrome rather than the BMI  had the
rognostic value for mortality in the CAD population [31–33]. In
ddition the underweight patients had the highest mortality rate
cross all BMI  classiﬁcations regardless of SUA levels indicating
he presence of obesity-mortality paradox phenomenon in patients
ith established CAD.
Finally, this study has some limitations to be addressed. First,
nly 89.2% patients had complete records for BMI  and SUAlogy 62 (2013) 354–360 359
examinations. Despite that, there was no signiﬁcant change in all
adjustment variables after the patients with missing data were
taken into account. This reﬂects the fact that the characteris-
tics of patients not enrolled were similar to those of patients
enrolled to analyze in the ET-CHD registry at baseline. Second,
we could not adjust some possible confounding factors at entry
due to pre-existing database such as the severity of heart failure
by echocardiographic evaluations and the complexity of coronary
artery lesions by angiographic estimations. Third, the magnitudes
of dynamic BMI  and SUA changes could not be obtained in follow-
up, which made it difﬁcult to assess the effects of these changes
on the mortality. Fourth, the central obesity measured by waist
circumference was not collected at entry and hence we could
not correlate levels of BMI  or SUA to how many components of
metabolic syndrome were involved and the related mortality risk.
In conclusion, among patients with established CAD, SUA may
be a potent predictor of mortality in overweight or obese patients.
Moreover, the obesity-mortality paradox phenomenon was mainly
driven by higher mortality risk in underweight patients and lower
mortality risk in overweight and obese patients with low SUA.
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